Try our BETA version of Cell type Prediction now for free

Contact us
  • Species: human
  • Number of cells: 4162
  • Number of downloads: 14
  • Study size: 42MB
  • Uploaded at: May 27, 2021

ImmunologyAtherosclerosisCarotid artery plaque

Single-cell immune landscape of human atherosclerotic plaques (scRNA-seq - T cells - Plaque)

Dawn M. Fernandez, Adeeb H. Rahman, Nicolas F. Fernandez, Aleksey Chudnovskiy, El-ad David Amir, Letizia Amadori, Nayaab S. Khan, Christine K. Wong, Roza Shamailova, Christopher A. Hill, Zichen Wang, Romain Remark, Jennifer R. Li, Christian Pina, Christopher Faries, Ahmed J. Awad, Noah Moss, Johan L. M. Bjorkegren, Seunghee Kim-Schulze, Sacha Gnjatic, Avi Ma’ayan, J Mocco, Peter Faries, Miriam Merad, Chiara Giannarelli

Atherosclerosis is driven by multifaceted contributions of the immune system within the circulation and at vascular focal sites. However, specific characteristics of dysregulated immune cells within atherosclerotic lesions that lead to clinical events such as ischemic stroke or myocardial infarction are poorly understood. Here, using single-cell proteomic and transcriptomic analyses, we uncovered distinct features of both T cells and macrophages in carotid artery plaques of patients with clinically symptomatic disease (recent stroke or transient ischemic attack) compared to asymptomatic disease (no recent stroke). Plaques from symptomatic patients were characterized by a distinct subset of CD4+ T cells and by T cells that were activated and differentiated. Moreover, some T cell subsets in these plaques presented markers of T cell exhaustion. Additionally, macrophages from these plaques contained alternatively activated phenotypes, including subsets associated with plaque vulnerability. In plaques from asymptomatic patients, T cells and macrophages were activated and displayed evidence of interleukin-1β signaling. The identification of specific features of innate and adaptive immune cells in plaques that are associated with cerebrovascular events may enable the design of more precisely tailored cardiovascular immunotherapies.

Back to datasets